Table 1.
Baseline characteristics of patients with rheumatoid arthritis who switched from anti-TNF monoclonal antibodies
| Overall (n = 89) | Abatacept (n = 25) | Tocilizumab (n = 38) | Etanercept (n = 26) | p value | |
|---|---|---|---|---|---|
| Age (year) | 58.7 ± 12.1 | 62.8 ± 9.3 | 56.7 ± 12.4 | 57.5 ± 13.3 | 0.315 |
| Sex (% female) | 82 | 80 | 78.9 | 88.5 | 0.593 |
| Disease duration (year) | 9.8 ± 8.3 | 11.4 ± 9.5 | 7.9 ± 6.1 | 11.0 ± 9.6 | 0.207 |
| Stage (I/II/III/IV, %) | 19.1/21.3/24.7/32.6 | 20.0/20.0/24.0/36.0 | 19.4/22.2/33.3/25.0 | 19.2/23.1/15.4/42.3 | 0.627 |
| Class (I/II/III/IV, %) | 13.5/50.6/29.2/4.5 | 12.0/52.0/36.0/0 | 16.8/52.8/27.8/2.8 | 11.5/50.0/26.9/11.5 | 0.453 |
| RF positive (%) | 82.9 | 70.6 | 78.6 | 96 | 0.002 |
| Previous biological DMARDs (%) | |||||
| Adalimumab | 37.1 | 60 | 26.3 | 30.8 | |
| Infliximab | 62.9 | 40 | 73.7 | 69.2 | |
| MTX use (%) | 78.7 | 80 | 73.7 | 84.6 | 0.567 |
| MTX dose (mg/week)a | 7.4 | 7.5 | 7.3 | 7.8 | 0.716 |
| Oral steroid use (%) | 58.4 | 64 | 59.5 | 53.8 | 0.760 |
| Oral steroid dose (mg/day)a | 4.2 | 3.8 | 4 | 4.8 | 0.433 |
| MMP-3 (ng/mL) | 257.0 ± 235.2 | 217.1 ± 190.0 | 317.4 ± 271.6 | 183.9 ± 129.0 | 0.371 |
| SJC, 0–28 | 5.4 ± 4.8 | 5.9 ± 5.6 | 5.7 ± 4.9 | 4.7 ± 3.7 | 0.546 |
| TJC, 0–28 | 6.4 ± 5.6 | 5.3 ± 4.1 | 6.0 ± 5.7 | 7.9 ± 6.6 | 0.439 |
| ESR (mm/h) | 53.1 ± 27.1 | 57.4 ± 32.1 | 51.1 ± 24.9 | 53.0 ± 26.4 | 0.475 |
| CRP (mg/dL) | 2.6 ± 2.6 | 1.7 ± 1.9 | 2.9 ± 2.8 | 3.0 ± 2.9 | 0.374 |
| GH-VAS 0–100 mm | 54.1 ± 22.9 | 53.7 ± 25.2 | 53.9 ± 22.4 | 54.6 ± 22.3 | 0.514 |
| DAS28-ESR | 5.3 ± 1.2 | 5.2 ± 1.2 | 5.3 ± 1.2 | 5.4 ± 1.3 | 0.267 |
| DAS28-CRP | 4.6 ± 1.2 | 4.4 ± 1.1 | 4.7 ± 1.2 | 4.8 ± 1.1 | 0.266 |
| CDAI | 22.4 ± 11.0 | 21.2 ± 11.0 | 22.4 ± 11.1 | 23.5 ± 11.2 | 0.266 |
| SDAI | 24.8 ± 11.6 | 23.1 ± 11.3 | 24.7 ± 11.5 | 26.4 ± 12.3 | 0.335 |
Data are presented as mean ± SD, unless otherwise indicated
Stage Steinbrocker stage, Class Steinbrocker class, RF rheumatoid factor, MTX methotrexate, MMP-3 matrix metalloproteinase-3, SJC swollen joint count, TJC tender joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, GH-VAS general health visual analog scale, DAS28 disease activity score in 28 joints, CDAI clinical disease activity index, SDAI simplified disease activity index
aMean among patients receiving the drug